Cutera Stock Price, News & Analysis

Cutera, Inc. (CUTR) is a medical technology company in the surgical and medical instrument manufacturing industry. According to company and news disclosures, Cutera focuses on aesthetic and dermatology solutions for practitioners worldwide, supplying energy-based medical aesthetic technologies used in face and body applications. The company has operated for more than 25 years and was established in the San Francisco Bay Area (Brisbane, California) by laser and optical engineers.

Cutera describes itself as providing medical aesthetic technologies that are driven by science and supported through partnerships with practitioners. Its offerings include systems and technologies used by medical and physician-led clinics to address aesthetic and dermatologic needs. Over time, Cutera has developed and marketed multiple branded platforms. Historical descriptions reference products such as xeo®, truSculpt® and excel V™, as well as excel HR™ and enlighten™, which is described as a picosecond and nanosecond high-powered laser system with two wavelengths.

In more recent communications, Cutera highlights AviClear as a breakthrough technology for the treatment of acne, noting growth in international capital system sales and efforts to expand access through training, education, practice development, cooperative marketing, launches in new international markets, and clinical indication expansion. The company also reports a focus on its global core capital systems and recurring service revenue, including field service and customer support.

Cutera’s activities extend beyond devices into selected distribution arrangements. For example, its Japanese subsidiary, Cutera KK, entered into an exclusive agreement with L’Oréal Japan Co. to promote, market, sell and distribute select SkinCeuticals® products to medical and physician-led clinics in Japan. Cutera has also reported skincare revenue in prior periods, and later disclosed the termination of a skincare distribution agreement, indicating that skincare distribution has been a complementary, but not primary, part of its business.

According to company releases, Cutera positions its technologies for use by practitioners in the medical aesthetics industry, including dermatology and aesthetic practices. The company emphasizes premium engineering, innovation, and service, and states that it aims to improve lives through medical aesthetic technologies. Its truFlex® muscle stimulation device is described as delivering energy to specific muscle groups in a short treatment session, covering a large body surface area and replicating a high number of muscle contractions to increase muscle mass in areas such as the abdomen, obliques, thighs, and glutes after a treatment series.

Cutera also engages in partnerships that showcase clinical and quality-of-life applications of its technologies. One example is its collaboration with the Adaptive Training Foundation and Dr. Edward Alvarez to provide truFlex muscle stimulation treatments to adaptive athletes undergoing a structured training program. A survey study referenced by the company evaluated improvements in quality of life and physical benefits from incorporating truFlex into that program, with participants reporting positive experiences and perceived improvements in muscle function in areas where they had struggled to progress.

From a corporate and capital structure perspective, Cutera has undergone significant change. In early 2025, the company announced that it was initiating a pre-packaged Chapter 11 financial restructuring with the support of a group of existing lenders. The plan aimed to reduce debt by nearly $400 million and raise $65 million of new money from those lenders, with the expectation that Cutera would emerge from the process as a private company with a stronger capital structure. Cutera stated that it would continue to operate and provide aesthetic and dermatology solutions throughout the court-supervised process, and that its non-U.S. entities were not included in the Chapter 11 filings.

On March 10, 2025, Cutera announced that it had formally notified The Nasdaq Stock Market LLC of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. The company stated that it expected to file a Form 25 with the U.S. Securities and Exchange Commission relating to the voluntary delisting of its common stock and, following the delisting, to file a Form 15 to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, including periodic reports such as Forms 10-K, 10-Q and 8-K. Cutera also noted that it had not arranged for listing or registration of the common stock on another national securities exchange or for quotation in a quotation medium, and could not guarantee that any public market for trading the common stock would exist.

On May 1, 2025, Cutera reported that it had successfully completed its financial restructuring and emerged from Chapter 11. The company stated that it reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from existing lenders. In connection with its emergence, Cutera indicated that it would operate as a private company backed by a consortium of investment firms. The company characterized this outcome as providing an enhanced capital structure and a significantly stronger balance sheet to support its growth strategy and continued development of aesthetic and dermatology solutions.

Prior to its decision to delist and restructure, Cutera’s public financial reports highlighted revenue derived from products and service, including capital systems and recurring revenue sources. The company has discussed cost restructuring programs, including a global restructuring program initiated in the fourth quarter of 2023 and additional cost reduction initiatives identified later, which were intended to improve its cost structure and organizational alignment.

For investors and practitioners reviewing CUTR as a historical stock, it is important to recognize that Cutera has transitioned from a Nasdaq-listed public company to a privately held entity following its Chapter 11 restructuring and voluntary delisting. The CUTR symbol therefore primarily represents the company’s historical public listing and associated trading history, while the ongoing business continues as a private company focused on aesthetic and dermatology technologies.

Business focus and industry role

Within the surgical and medical instrument manufacturing sector, Cutera’s disclosures emphasize energy-based medical aesthetic technologies and dermatology solutions for professional use. Its systems are positioned for practitioners seeking devices for face and body treatments, acne treatment, muscle stimulation, and related aesthetic applications. The company’s communications highlight scientific underpinnings, partnerships with practitioners, and global reach, including direct operations in North America and activities in markets such as Japan.

Key historical products and technologies

• Energy-based aesthetic platforms historically referenced by the company include xeo®, truSculpt®, excel V™, excel HR™, and enlighten™.
• AviClear is described as a breakthrough technology for the treatment of acne, with growth driven by international capital system sales and efforts to expand training, education, and clinical indications.
• truFlex® is presented as a muscle stimulation device targeting specific muscle groups, used in both aesthetic and adaptive athlete contexts.
• Cutera KK’s exclusive distribution of select SkinCeuticals® products in Japan illustrates the company’s role in distributing skincare products to medical and physician-led clinics alongside its device offerings.

Corporate transformation and trading status

Cutera’s recent history includes a notable capital structure transformation. The company entered into a pre-packaged Chapter 11 process supported by a significant portion of its lenders, with the stated goals of reducing debt and raising new capital. It then voluntarily delisted its common stock from Nasdaq, indicated its intention to suspend SEC reporting obligations via a Form 15, and later announced its emergence from Chapter 11 as a private company owned by a consortium of investment firms. These steps mark a transition from public to private ownership while maintaining operations in the medical aesthetics and dermatology sector.

Use of CUTR information on Stock Titan

On Stock Titan, the CUTR overview page serves as a reference for the historical public company, its business focus in aesthetic and dermatology solutions, and the restructuring and delisting events that affected its trading status. Users can review how Cutera positioned its technologies, the types of partnerships it pursued, and the key milestones that led to its current status as a private company.